# Pharvaris N.V. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Pharvaris N.V.). ## Overview Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with initial emphasis on angioedema and other bradykinin-mediated conditions. The group is organized through subsidiaries in the Netherlands, the United States, and Switzerland, with its corporate base in Leiden, the Netherlands. ## Products & services • Oral therapies for hereditary angioedema and related bradykinin-mediated diseases • Development-stage rare disease drug candidates • Clinical development and regulatory approval programs • Commercialization planning for future approved therapies - **Rare disease therapeutics** (100%) — Drug candidates and planned medicines for rare bradykinin-mediated disorders such as angioedema. - Oral therapies for hereditary angioedema and related bradykinin-mediated diseases - Development-stage rare disease drug candidates - Clinical development and regulatory approval programs - Commercialization planning for future approved therapies ## Customers Pharvaris does not sell broad consumer products; its end users are patients with rare bradykinin-mediated diseases, while its immediate commercial counterparts are physicians, specialty distributors, and healthcare systems that would prescribe, stock, and administer approved therapies. In the development stage, the company’s economic relationship is primarily with regulators, investigators, clinical sites, and future payers that determine access and reimbursement. Rare-disease treatments are typically bought because they address serious unmet medical need and can offer differentiated convenience or efficacy. - **Patients with rare bradykinin-mediated diseases** (primary) — Potential end users of the company's therapies, seeking prevention or treatment of angioedema attacks. - **Specialist physicians** (primary) — Allergists, immunologists, and other specialists who diagnose and prescribe therapies. - **Payers and reimbursement authorities** (secondary) — They determine formulary access, coverage, and patient affordability after approval. - **Clinical trial sites** (primary) — Hospitals and research centers that enroll patients and generate development data. - Patients with hereditary angioedema and related rare diseases - Specialist physicians who prescribe targeted rare-disease therapies - Hospitals and specialty pharmacies that may dispense treatment - Payers and reimbursement bodies that determine access after approval - Clinical investigators and trial sites supporting development ## Geography Pharvaris is headquartered in Leiden, the Netherlands, and operates through entities in the Netherlands, the United States, and Switzerland. The available reports do not disclose revenue by geography, which is consistent with a development-stage company that has not yet established broad commercial sales. Its geographic footprint matters mainly for clinical operations, regulatory submissions, intellectual property, and future market launch planning across the U.S. and Europe. - Headquartered in Leiden, the Netherlands - Operating subsidiaries in the United States and Switzerland - Clinical and regulatory activity spans U.S. and European markets - No disclosed revenue by country in the provided excerpts - Geography matters more for trials, approvals, and future launch rights ## Strategy The company’s strategy is to advance its rare-disease pipeline through clinical development and regulatory review, then position candidate therapies for commercialization if approved. It is also building the operational and corporate structure needed to support global development and future launch in target markets where hereditary angioedema is treated. Protecting intellectual property and maintaining access to funding are central because the model depends on completing long development cycles before meaningful product revenue. - **Late-stage clinical development** (short-term) — Progressing candidates through trials is the main value driver before any product revenue exists. - **Regulatory pathway execution** (medium-term) — Approval is required before the company can monetize its pipeline. - **Commercial readiness** (medium-term) — Rare-disease launches require medical affairs, market access, and distribution capabilities. - Advance rare-disease drug candidates through late-stage development - Target angioedema and other bradykinin-mediated diseases first - Prepare for regulatory approval and future commercialization - Maintain global corporate and operating capabilities - Protect IP and know-how around product candidates ## Risks Pharvaris faces the typical biotechnology risks of clinical failure, regulatory delay, and difficulty raising capital before product revenue is established. The company also depends on intellectual property protection, manufacturing readiness, and eventual market acceptance in a rare-disease market where reimbursement and launch execution are critical. Because its business is still development-focused, any setback in trials or approvals could materially affect valuation and future financing needs. - **Clinical development failure** [critical] — The business depends on proving that its product candidates are safe and effective in rare diseases. - **Regulatory approval risk** [critical] — Commercialization requires approval from the FDA and other agencies, which may impose delays or restrictions. - **Financing risk** [high] — Development-stage biotech typically consumes cash before generating product sales and may need new capital. - **Intellectual property risk** [high] — Loss of patent or know-how protection could reduce the value of the pipeline and future exclusivity. - Clinical trials may fail to show safety or efficacy - Regulatory approval could be delayed or denied - Capital needs may require dilutive financing - Manufacturing scale-up could limit launch readiness - IP disputes could weaken exclusivity or freedom to operate ## Accounting The most important accounting judgments are around development-stage expenses, share-based financing, and lease-related obligations rather than product revenue. The interim financial statements also highlight historical-cost presentation, foreign exchange effects, and estimates used in a going-concern assessment, all of which can influence reported cash runway and equity balances. Because the company has no disclosed commercial revenue in the excerpts, investors should watch how capital raises, lease liabilities, and future development spending flow through the statements. - **Development-stage expense recognition** — Materially affects operating loss and cash burn - **Share issuance accounting** — Affects liquidity and dilution - **Lease accounting** — Affects cash flow classification and balance sheet obligations - **Going concern assessment** — Important for liquidity disclosure and investor confidence - **Foreign currency translation** — Can create exchange-rate gains or losses in cash and equity - No product revenue disclosed in the excerpts - Development costs and trial expenses drive reported losses - Share issuance affects equity and financing cash flow - Lease liabilities create recurring IFRS 16 accounting entries - Foreign exchange movements affect euro-denominated reporting --- *Last updated: 2026-09-28T12:13:41.271183+00:00*